Genetic Determinants of Opioids Analgesia

This study has been completed.

First Received on September 12, 2005. Last Updated on October 28, 2008 History of Changes

Sponsor:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00226564

Purpose

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.

The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Condition	Intervention
Nephrolithiasis	Drug: Alfentanil

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Resource links provided by NLM:

Genetics Home Reference related topics: Help Me Understand Genetics

MedlinePlus related topics: Kidney Stones

Drug Information available for: Alfentanil hydrochloride Alfentanil

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

Total alfentanil dose used during the procedure.
The extent of respiratory depression.

Estimated Enrollment:	100
Study Start Date:	August 1997

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age > 20

Exclusion Criteria:

Regular use of opioid drugs
Known hypersensitivity to alfentanil

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226564

Locations

Israel
Hadassah Medical Organization
Jerusalem, Israel

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:

Yoseph Caraco, MD

Hadassah Medical Organization

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00226564 History of Changes
Other Study ID Numbers:	yc19554-HMO-CTIL
Study First Received:	September 12, 2005
Last Updated:	October 28, 2008
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:

Nephrolithiasis
Kidney Diseases
Urologic Diseases
Urolithiasis
Alfentanil
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs

Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Anesthetics, Intravenous
Anesthetics, General
Anesthetics

ClinicalTrials.gov processed this record on February 12, 2012